Scarica l'app Stockscreener
18.12
0.93%
-0.17
Dopo l'orario di chiusura:
19.02
0.90
+4.97%
Precedente Chiudi:
$18.29
Aprire:
$19.5
Volume 24 ore:
169.79K
Relative Volume:
1.05
Capitalizzazione di mercato:
$649.58M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-20.07%
1M Prestazione:
-24.06%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$18.00
$19.89
Intervallo di 1 settimana:
$18.00
$22.87
Portata 52W:
$18.00
$26.62
Bioage Labs Inc Stock (BIOA) Company Profile
Nome
Bioage Labs Inc
Settore
Telefono
510-806-1445
Indirizzo
1445A SOUTH 50TH STREET, RICHMOND
Confronta BIOA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| BIOA | 18.12 | 649.58M | 0 | 0 | 0 | 0.00 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Bioage Labs Inc Borsa (BIOA) Ultime notizie
BioAge Labs Reports Strong Q3 2024 Achievements - Yahoo Finance
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
BioAge Labs Reports Q3 Loss, Secures $334.5M Cash Runway Through 2029 After IPO | BIOA Stock News - StockTitan
BioArctic AB Sets Q3 2024 Earnings Call for November 14: Key Details Inside | BIOA Stock News - StockTitan
BioAge Labs, Inc. to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 - Marketscreener.com
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 - GlobeNewswire
BioAge Labs to Present at Jefferies London Healthcare Conference - GlobeNewswire
Citi sets BioAge Labs Buy stock rating on obesity drug potential - Investing.com
BioAge Labs initiated with an Overweight at Morgan Stanley - MSN
Goldman Sachs, Morgan Stanley bullish on BioAge, cite Lilly relationship - MSN
Goldman Sachs, Morgan Stanley bullish on BioAge, cite Lilly relationship (NASDAQ:BIOA) - Seeking Alpha
Morgan Stanley sets BioAge stock at Overweight rating, cites Lilly tie-up - Investing.com Australia
Wall Street analysts initiate coverage of BioAge Labs By Investing.com - Investing.com Canada
BioAge Labs stock initiated at buy, key obesity trial data expected by 2025 – Jefferies - Investing.com Canada
Morgan Stanley sets BioAge stock at Overweight rating, cites Lilly tie-up By Investing.com - Investing.com South Africa
Prediction: These 2 Stocks Could Soar in 2025 - Yahoo Finance
Stocks To Watch: BioAge Labs Sees Relative Strength Rating Jump To 94 - Investor's Business Daily
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock - Yahoo! Voices
RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc - Yahoo Finance
BioAge Labs’ $238 Million Upsized Initial Public Offering - Global Legal Chronicle
3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October - MSN
Bioage Labs director acquires $4.3m in common stock By Investing.com - Investing.com UK
Bioage Labs director acquires $4.3m in common stock - Investing.com
This IPO Biotech Stock Could Be the Next Eli Lilly - The Motley Fool
Cormorant Asset Management buys $8.1m in BioAge Labs stock - Investing.com India
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement - The Manila Times
BioAge Labs Announces Closing of Initial Public Offering, - GlobeNewswire
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement - ForexTV.com
Cormorant Asset Management buys $8.1m in BioAge Labs stock By Investing.com - Investing.com South Africa
Fenwick Represents BioAge Labs in $238 Million Upsized Initial Public Offering and Concurrent Private Placement - Fenwick & West LLP
BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival (NASDAQ:BIOA) - Seeking Alpha
BioAge Labs director Enright buys $7.2 million in stock - Investing.com India
Finance Watch: BioAge Raises $198m In 20th Biopharma IPO Of 2024 - Scrip
Wave financing, BioAge IPO help biotech end September strong - BioCentury
BioAge Labs director Pande Vijay Satyanand buys $16.2m in stock - Investing.com Australia
BioAge Labs director Pande Vijay Satyanand buys $16.2m in stock By Investing.com - Investing.com South Africa
BioAge Labs director Enright buys $7.2 million in stock By Investing.com - Investing.com Australia
Bioage Labs Inc Azioni (BIOA) Dati Finanziari
Non sono disponibili dati finanziari per Bioage Labs Inc (BIOA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.79%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):